A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 23 Jan 2019
At a glance
- Drugs Capecitabine (Primary) ; Temozolomide (Primary)
- Indications Adenocarcinoma; Glucagonoma; Insulinoma; Neuroendocrine tumours; Pancreatic cancer
- Focus Therapeutic Use
- 16 Jan 2019 Planned primary completion date changed from 1 Jul 2018 to 1 Jun 2019.
- 31 Aug 2018 Biomarkers information updated
- 05 Jun 2018 Results (n=144) presented at the 54th Annual Meeting of the American Society of Clinical Oncology.